What is the primary purpose of this debt offering?

The primary purpose of this debt offering is to raise capital. While not explicitly stated, the substantial amount raised typically supports Eli Lilly's ongoing research and development activities, clinical trials, potential acquisitions, and other general corporate purposes to fuel its growth and pipeline expansion.

How much debt did Eli Lilly issue in total?

Eli Lilly issued a total of $6,750,000,000 aggregate principal amount of notes. After deductions for underwriting discounts and before estimated offering expenses, the company realized net proceeds of approximately $6.46 billion.

What are the interest rates and maturity dates of the notes issued?

The notes issued have the following characteristics: 4.550% Notes due 2028 ($1B), 4.750% Notes due 2030 ($1.25B), 4.900% Notes due 2032 ($1B), 5.100% Notes due 2035 ($1.25B), 5.500% Notes due 2055 ($1.25B), and 5.600% Notes due 2065 ($750M).

Does this debt offering impact existing shareholders directly?

This debt offering does not directly impact existing shareholders in terms of share dilution, as it involves the issuance of debt rather than equity. However, the successful deployment of these funds for growth initiatives could positively impact the company's long-term value and, consequently, shareholder returns. The increased debt will, however, increase the company's leverage.

LLY 8-K SEC Disclosure — Feb 12, 2025

Summary

Eli Lilly and Company (LLY) has filed an 8-K detailing a significant debt offering, successfully raising approximately $6.46 billion in net proceeds through the issuance of various senior notes. The offering includes $1 billion in 4.550% Notes due 2028, $1.25 billion in 4.750% Notes due 2030, $1 billion in 4.900% Notes due 2032, $1.25 billion in 5.100% Notes due 2035, $1.25 billion in 5.500% Notes due 2055, and $750 million in 5.600% Notes due 2065. This substantial capital raise will likely be utilized to support the company's ongoing research and development, clinical trials, and potential future acquisitions, aligning with its strategy to expand its product pipeline and market presence. Investors should note the diverse maturity profile and interest rates of these notes, reflecting current market conditions and Lilly's borrowing costs. The company has secured capital across short, medium, and long-term horizons, which can provide financial flexibility. The offering was registered on a Form S-3 registration statement, indicating a routine debt issuance for a company of Lilly's size and financial standing. The specifics of the underwriting agreements and note indentures are detailed in the filed exhibits for those seeking deeper financial insight.

Key Highlights

1Eli Lilly and Company raised approximately $6.46 billion in net proceeds from a debt offering.
2The offering consisted of six tranches of senior notes with varying maturities and interest rates, ranging from 2028 to 2065.
3The notes issued include: $1B of 4.550% Notes due 2028, $1.25B of 4.750% Notes due 2030, $1B of 4.900% Notes due 2032, $1.25B of 5.100% Notes due 2035, $1.25B of 5.500% Notes due 2055, and $750M of 5.600% Notes due 2065.
4The debt offering was conducted through an underwriting agreement with major financial institutions, including Barclays, BofA Securities, Citigroup, Deutsche Bank, and Goldman Sachs.
5The offering was registered under a Form S-3 registration statement, a standard procedure for public companies issuing new securities.
6The company has the option to redeem the notes, in whole or in part, under specific terms and conditions outlined in the respective indentures.
7The proceeds are expected to fund general corporate purposes, likely including R&D, clinical trials, and strategic initiatives.

ELI LILLY & Co 8-K Report, Corporate Update (Feb 12, 2025)

Summary

Key Highlights

Frequently Asked Questions